Print page content Print
Increase text size Decrease text size
Text Size

safety information

CYTOPOINT® safety information

CYTOPOINT is a safe choice for virtually every dog

  • No known drug interactions—safe in combination with other medications, including1:

    • APOQUEL® (oclacitinib tablet), corticosteroids, cyclosporine and antihistamines
    • Treatments such as parasiticides, antibiotics, antifungals, vaccines, NSAIDs and allergen-specific immunotherapy
  • Targeted mechanism of action may help minimize side effects and avoid unwanted effects on immune function1

  • Does not burden the liver or kidneys

    • CYTOPOINT functions like naturally occurring antibodies and is eliminated via normal protein degradation pathways in the same way, which does not involve the liver or kidneys
  • Safe to use in dogs of any age2

    • Can be used in dogs with concomitant diseases

CYTOPOINT is safe for long-term use

  • Safety in a 7-month laboratory study2

    • CYTOPOINT was shown to be safe when administered to laboratory Beagles at up to 5 times the label dose (10 mg/kg) monthly for 7 months. No treatment effects on clinical observations or clinical pathology were identified
  • Ongoing safety monitoring

    • Ongoing pharmacovigilance monitoring, beginning in July 2015, continues to show a safety profile similar to that seen in clinical trials

Indications: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.



Mon–Fri, 8:30am–8:00pm ET

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2022 Zoetis Services LLC. All rights reserved.